Antifugal Effect of Recombinant Human Granulocyte-macrophage Stimulating Factor (rhGM-CSF) in Patients Post Allo-HSCT
Phase 4
Completed
- Conditions
- Mycoses
- Interventions
- First Posted Date
- 2010-11-02
- Last Posted Date
- 2014-11-04
- Lead Sponsor
- Xiamen Amoytop Biotech Co., Ltd.
- Target Recruit Count
- 206
- Registration Number
- NCT01232504
- Locations
- 🇨🇳
The First Affiliated Hospital of Guangxi Medical University, Nanning, Guangxi, China
🇨🇳Henan Cancer Hospital, Zhengzhou, Henan, China
🇨🇳The First Affiliated Hospital of Xinjiang Medical University, Urumqi, Xinjiang, China
Efficacy and Safety of Ypeginterferon Alfa-2b in HBeAg Positive Chronic Hepatitis B
Phase 2
Completed
- Conditions
- Chronic Hepatitis B
- Interventions
- First Posted Date
- 2010-06-14
- Last Posted Date
- 2013-02-04
- Lead Sponsor
- Xiamen Amoytop Biotech Co., Ltd.
- Target Recruit Count
- 205
- Registration Number
- NCT01143662
- Locations
- 🇨🇳
Tianjin Third Central Hospital, Tianjin, China
🇨🇳First Affiliated Hospital of Wenzhou Medical College, Wenzhou, China
🇨🇳Tangdu Hospital, Fourth Military Medical University, Xian, China
Efficacy and Safety of Ypeginterferon Alfa-2b in Chronic Hepatitis C
Phase 2
Completed
- Conditions
- Chronic Hepatitis C
- Interventions
- First Posted Date
- 2010-06-10
- Last Posted Date
- 2013-02-04
- Lead Sponsor
- Xiamen Amoytop Biotech Co., Ltd.
- Target Recruit Count
- 211
- Registration Number
- NCT01140997
- Locations
- 🇨🇳
302 Military Hospital, Beijing, China
🇨🇳Peking University People's Hospital, Beijing, China
🇨🇳Xiangya Second Hospital, Central-south University, Changsha, China
© Copyright 2025. All Rights Reserved by MedPath